J. Vardiman, J. Thiele, and D. Arber, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-951, 2009.
DOI : 10.1182/blood-2009-03-209262

Q. Wang, T. Stacy, and J. Miller, The CBF?? Subunit Is Essential for CBF??2 (AML1) Function In Vivo, Cell, vol.87, issue.4, pp.697-708, 1996.
DOI : 10.1016/S0092-8674(00)81389-6

H. Dombret, C. Preudhomme, and N. Boissel, Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?, Current Opinion in Hematology, vol.16, issue.2, pp.92-97, 2009.
DOI : 10.1097/MOH.0b013e3283257b18

J. Yin, O. Brien, M. Hills, and R. , Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial, Blood, vol.120, issue.14, pp.2826-2835, 2012.
DOI : 10.1182/blood-2012-06-435669

N. Boissel, H. Leroy, and B. Brethon, Incidence and prognostic impact of c-Kit, FLT3 and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML), Leukemia, vol.102, issue.6, pp.965-970, 2006.
DOI : 10.1182/blood-2003-03-0880

P. Paschka, G. Marcucci, and A. Ruppert, Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.24, issue.24, pp.3904-3911, 2006.
DOI : 10.1200/JCO.2006.06.9500

P. Paschka, J. Du, and R. Schlenk, Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG), Blood, vol.121, issue.1, pp.170-177, 2013.
DOI : 10.1182/blood-2012-05-431486

E. Jourdan, N. Boissel, and S. Chevret, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, vol.121, issue.12, pp.2213-2223, 2013.
DOI : 10.1182/blood-2012-10-462879

S. Schwartz, A. Heinecke, and M. Zimmermann, Expression of the C-Kit Receptor (CD117) is a Feature of Almost All Subtypes of De Novo Acute Myeloblastic Leukemia (AML), Including Cytogenetically Good-Risk AML, and Lacks Prognostic Significance, Leukemia & Lymphoma, vol.15, issue.1-2, pp.85-94, 1999.
DOI : 10.1056/NEJM199303043280904

J. Gabert, E. Beillard, and V. Van-der-velden, Standardization and quality control studies of ???real-time??? quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia ??? A Europe Against Cancer Program, Leukemia, vol.25, issue.Suppl 2, pp.2318-2357, 2003.
DOI : 10.1006/meth.2001.1262

N. Mantel and D. Byar, Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data, Journal of the American Statistical Association, vol.1, issue.3, pp.81-86, 1974.
DOI : 10.1080/01621459.1974.10480130

D. Cox, Regression Models and Life-Tables, J R Stat Soc Series B Stat Methodol, vol.34, pp.187-202, 1972.
DOI : 10.1007/978-1-4612-4380-9_37

M. Schittenhelm, S. Shiraga, and A. Schroeder, Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies, Cancer Research, vol.66, issue.1, pp.473-481, 2006.
DOI : 10.1158/0008-5472.CAN-05-2050

O. Hare, T. Walters, D. Stoffregen, and E. , Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants, Cancer Research, vol.65, issue.11, pp.4500-4505, 2005.
DOI : 10.1158/0008-5472.CAN-05-0259

N. Shah, H. Kantarjian, and D. Kim, Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia, Journal of Clinical Oncology, vol.26, issue.19, pp.3204-3212, 2008.
DOI : 10.1200/JCO.2007.14.9260

R. Gale, C. Green, and C. Allen, The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia, Blood, vol.111, issue.5, pp.2776-2784, 2008.
DOI : 10.1182/blood-2007-08-109090

P. Kottaridis, R. Gale, and S. Langabeer, Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors, Blood, vol.100, issue.7, pp.2393-2398, 2002.
DOI : 10.1182/blood-2002-02-0420

C. Allen, R. Hills, and K. Lamb, The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia, Leukemia, vol.10, issue.9, pp.1891-1901, 2013.
DOI : 10.1111/j.1365-2141.2006.06276.x

R. Cairoli, A. Beghini, and E. Morello, Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations, Leukemia Research, vol.29, issue.4, pp.397-400, 2005.
DOI : 10.1016/j.leukres.2004.10.005